BMJ medicine · 2026
Modelling lowering of raised blood pressure in pregnancy to reduce pre-eclampsia: secondary analysis of data from prospective cohort studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wright Alan, Syngelaki Argyro, Wright David, von Dadelszen Peter, Nicolaides Kypros H, Magee Laura A
Аннотация
OBJECTIVE: To determine whether antihypertensive treatment of blood pressure levels of <140/90 mm Hg can reduce the incidence of pre-eclampsia.
DESIGN: Secondary analysis of data from prospective cohort studies.
SETTING: Three prospective screening studies of women who attended routine hospital maternity visits at 11-13 weeks' gestation, 1 February 2010 to 31 December 2016. Participants were from seven secondary care institutions in England.
PARTICIPANTS: 54 422 pregnancies screened at 11-13 weeks' gestation for pre-eclampsia and with blood pressure values available, that resulted in a liveborn or stillborn infant at ≥24 weeks' gestation.
MAIN OUTCOME MEASURES: Incidence of pre-eclampsia (overall, and at preterm or term gestational ages), according to modelled blood pressure lowering.
RESULTS: The study population was ethnically diverse (17.3% black participants, 7.8% from South or East Asia, and 2.6% self-identified with more than one ethnic group). The Fetal Medicine Foundation competing risks model was used to calculate the expected risk of pre-eclampsia, based on maternal characteristics, mean arterial pressure, uterine artery pulsatility index, and placental growth factor. The expected risk of pre-eclampsia was used to calculate the expected incidence of pre-eclampsia. Reducing diastolic blood pressure from >85 mm Hg to a target of 85 mm Hg would mean that 4.8% of women would be offered antihypertensive drugs, with a potential relative risk reduction of 21.4% (absolute reduction of 2.9%) in any pre-eclampsia and 28.3% (absolute reduction of 1.4%) reduction in preterm pre-eclampsia. By reducing diastolic blood pressure from >80 mm Hg to a target of 80 mm Hg, 13.2% of women would receive antihypertensive drugs, with a potential relative risk reduction of 26.0% (absolute reduction of 2.3%) in any pre-eclampsia and 33.8% (absolute reduction of 1.0%) reduction in preterm pre-eclampsia. By reducing diastolic blood pressure from >75 mm Hg to a target of 75 mm Hg, 29.5% of women would receive antihypertensive drugs, with a potential relative risk reduction of 32.8% (absolute reduction of 2.1%) in any pre-eclampsia and 41.6% (absolute reduction of 0.8%) in preterm pre-eclampsia.
CONCLUSIONS: Lowering blood pressure from early pregnancy may reduce preterm and term pre-eclampsia. This finding requires evaluation in a definitive randomised trial.
DESIGN: Secondary analysis of data from prospective cohort studies.
SETTING: Three prospective screening studies of women who attended routine hospital maternity visits at 11-13 weeks' gestation, 1 February 2010 to 31 December 2016. Participants were from seven secondary care institutions in England.
PARTICIPANTS: 54 422 pregnancies screened at 11-13 weeks' gestation for pre-eclampsia and with blood pressure values available, that resulted in a liveborn or stillborn infant at ≥24 weeks' gestation.
MAIN OUTCOME MEASURES: Incidence of pre-eclampsia (overall, and at preterm or term gestational ages), according to modelled blood pressure lowering.
RESULTS: The study population was ethnically diverse (17.3% black participants, 7.8% from South or East Asia, and 2.6% self-identified with more than one ethnic group). The Fetal Medicine Foundation competing risks model was used to calculate the expected risk of pre-eclampsia, based on maternal characteristics, mean arterial pressure, uterine artery pulsatility index, and placental growth factor. The expected risk of pre-eclampsia was used to calculate the expected incidence of pre-eclampsia. Reducing diastolic blood pressure from >85 mm Hg to a target of 85 mm Hg would mean that 4.8% of women would be offered antihypertensive drugs, with a potential relative risk reduction of 21.4% (absolute reduction of 2.9%) in any pre-eclampsia and 28.3% (absolute reduction of 1.4%) reduction in preterm pre-eclampsia. By reducing diastolic blood pressure from >80 mm Hg to a target of 80 mm Hg, 13.2% of women would receive antihypertensive drugs, with a potential relative risk reduction of 26.0% (absolute reduction of 2.3%) in any pre-eclampsia and 33.8% (absolute reduction of 1.0%) reduction in preterm pre-eclampsia. By reducing diastolic blood pressure from >75 mm Hg to a target of 75 mm Hg, 29.5% of women would receive antihypertensive drugs, with a potential relative risk reduction of 32.8% (absolute reduction of 2.1%) in any pre-eclampsia and 41.6% (absolute reduction of 0.8%) in preterm pre-eclampsia.
CONCLUSIONS: Lowering blood pressure from early pregnancy may reduce preterm and term pre-eclampsia. This finding requires evaluation in a definitive randomised trial.